Contact Us

Marwood provides multinational policy and market insights to healthcare companies, investors and lenders through transaction support, strategic advisory and retainer engagements

With a focus on the UK and the EU policy, regulatory, funding, and reimbursement dynamics, we work with our clients to assess the risk and opportunities that result from government action on the national or local level across a broad range of healthcare sectors and markets. In addition, we provide support on transatlantic transactions through our dedicated US and Marwood's International team.
International team members is comprised of veterans of the Department of Health, NHS England, Local Authorities, private health insurers, and national care providers. With key lines of inquiry designed to generate insight into the current and future healthcare landscape and key factors our clients should consider when investing in the sector, our seasoned advisory team leverages a vast network of internal and external resources, relevant key stakeholder groups, and key opinion leaders to ensure conclusions are supported by multiple sources.

Marwood has Extensive International Experience Across Multiple Healthcare Subsectors

See Marwood's international experience in the fertility service space...
  • Canada
  • Britain
  • US
  • Switzerland
  • Chile
  • Ukraine
  • Brazil
  • Cyprus
  • France
  • Saudi Arabia
  • Spain
  • India
  • Sweden
  • China
  • Germany
  • Russia
  • Italy
  • Australia
Marwood has conducted policy, reimbursement, market strategy and operational work across all major subsectors:
  • IVF
  • IUI
  • Egg/sperm banking
  • Genetic testing
  • Egg donation
  • Surrogacy

See how Marwood supported a European asset manager's investment in an international speciality pharmaceutical company...

Marwood Case Study

Engagement Purpose

A European alternative asset management firm sought Marwood’s assistance in evaluating the risks and opportunities associated with a potential investment in a publicly-traded international specialty pharmaceuticals company. The Company manufactures specialty pharmaceutical products, including branded and generic prescriptions, through wholesalers, hospitals and pharmacies in nearly 100 countries around the world. Marwood analyzed the Company’s UK business line specifically.

Marwood Analysis

  • Evaluated overarching pricing and volume outlook for the Company’s product lines in the UK
  • Analyzed the potential risk of the Company being investigated by the Competition and Markets Authority for an abuse of a dominant position
  • Assessed the impact of the proposed Health Service Medical Supplies (Costs) Bill within the UK
  • Provided insights as to the Company’s reputation with key national and local decision makers within the UK

Key Findings

Marwood concluded that the Company would experience some pricing pressure coming from specific legislative and regulatory changes, however, overall volumes were expected to remain stable. Marwood assessed that though the Company had recently gone under reputational damage, it was mostly among local decision makers who did not have significant direct influence on national purchasing decisions.

Illustrative example only*